EMBARGOED FOR RELEASE: 3 P.M. (CT) TUESDAY, FEBRUARY 12, 2013
Media Advisory: To contact corresponding author Feiko O. ter Kuile, Ph.D., email firstname.lastname@example.org.
CHICAGO – Among pregnant women in sub-Saharan Africa, intermittent preventive therapy for malaria with 3 or more doses of the drug regimen sulfadoxine-pyrimethamine was associated with a higher birth weight and lower risk of low birth weight than the current standard 2-dose regimen, according to a review and meta-analysis of previous studies published in the February 13 issue of JAMA.
“Intermittent preventive therapy with sulfadoxine-pyrimethamine to control malaria during pregnancy is used in 37 countries in sub-Saharan Africa, and 31 of those countries use the standard 2-dose regimen. However, 2 doses may not provide protection during the last 4 to 10 weeks of pregnancy, a pivotal period for fetal weight gain,” according to background information in the article. “Furthermore, increasing sulfadoxine-pyrimethamine resistance, which results in a progressive decrease of the duration of the prophylactic effect, may also require more frequent dosing.”
Kassoum Kayentao, M.D., of the Liverpool School of Tropical Medicine, Liverpool, United Kingdom, and colleagues conducted a review and meta-analysis to evaluate whether 3 or more doses of intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine are associated with higher birth weight or a lower risk of low birth weight (LBW; less than 5.5 lbs.) than a 2-dose regimen. After a review of the medical literature, the researchers identified 7 trials that met inclusion criteria. These trials included 6,281 pregnancies.
Analysis of the data indicated that women in the ≥ 3-dose group had a 20 percent lower risk of having a LBW infant. The absolute risk reduction was 33 per 1,000 women, from a median (midpoint) risk of 167 per 1,000 in the 2-dose group to 134 per 1,000 in the ≥ 3-dose recipients (number needed to treat = 31). The median birth weight in the 2-dose group was 6.3 lbs., and on average 2 ounces higher in the ≥ 3-dose group.
“The association was consistent across a wide range of sulfadoxine-pyrimethamine resistance. There was no evidence of small-study bias. The ≥ 3-dose group had less placental malaria,” the authors write. “There were no differences in rates of serious adverse events.”
“These data provide support for the new World Health Organization (WHO) recommendation that intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine be provided at each scheduled focused antenatal-care [before birth] visit in the second and third trimesters in all settings in which intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine is recommended. Future research should focus on how best to implement the updated WHO guidelines for intermittent preventive therapy during pregnancy with sulfadoxine-pyrimethamine and specifically their integration with focused antenatal care. Continued monitoring of the association between population-level sulfadoxine-pyrimethamine resistance and the effectiveness of intermittent preventive therapy during pregnancy is required,” the researchers conclude.
(JAMA. 2013;309(6):594-604; Available pre-embargo to the media at http://media.jamanetwork.com)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
# # #